Hospital
ST Elizabeth Medical Center
ST Elizabeth Medical Center was paid $27.51M by Medicaid between Jan 2018 and Oct 2023, across 350 billing codes. Its largest line is 99285, emergency room visit (most serious) — 9.5% of everything it billed.
33Billing provider infoST ELIZABETH MEDICAL CENTER
UTICA, NY 13501
UTICA, NY 13501
33aNPI1821093402assigned 06/20/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$27.51M
24GClaims959,850
24DCodes billed350
24AFirst – last monthJan 2018 – Oct 2023
Compared with peers
Next to other General Acute Care Hospital providers in New York
Rank by total paid#48 of 231
Median peer was paid$561K
This provider vs. median49×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 36,746 | $1.57M | |
| 2019 | 91,578 | $2.36M | |
| 2020 | 204,118 | $5.27M | |
| 2021 | 226,906 | $6.13M | |
| 2022 | 197,891 | $6.33M | |
| 2023 | 202,611 | $5.86M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.5% | 13,893 | 13,293 | $2.62M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.2% | 13,416 | 12,854 | $1.97M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.1% | 12,438 | 11,931 | $1.96M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 6.0% | 53,006 | 50,987 | $1.64M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 4.3% | 16,697 | 14,070 | $1.20M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.6% | 2,930 | 2,887 | $981K |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.4% | 5,648 | 5,042 | $923K |
| 80053 | Comprehensive metabolic panel | 3.0% | 56,023 | 52,282 | $813K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.9% | 2,799 | 2,741 | $810K |
| 97597 | 2.4% | 4,905 | 2,526 | $656K | |
| G0378 | Hospital observation service, per hour | 2.3% | 503 | 464 | $626K |
| 36415 | Collection of venous blood by venipuncture | 1.8% | 82,359 | 45,630 | $491K |
338 more codes
| 99214 | Doctor's office visit, returning patient (more involved) | 1.7% | 10,012 | $476K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.6% | 3,278 | $432K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.6% | 9,441 | $427K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.5% | 1,230 | $426K |
| 90791 | Psychiatric diagnostic evaluation | 1.3% | 2,521 | $366K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.3% | 3,104 | $349K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.2% | 11,299 | $338K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 2,231 | $302K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.1% | 857 | $290K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 1.0% | 7,944 | $282K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 6,870 | $257K |
| 94060 | <1% | 1,396 | $254K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 4,632 | $252K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 8,072 | $240K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 22,245 | $222K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 968 | $206K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 32,368 | $200K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,497 | $194K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 7,981 | $193K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 3,554 | $182K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 7,953 | $176K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 1,722 | $171K |
| 93458 | <1% | 90 | $170K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 55,067 | $167K |
| 80061 | Lipid panel | <1% | 21,288 | $163K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,795 | $161K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 16,431 | $153K |
| 83880 | <1% | 3,827 | $130K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 12,887 | $125K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 1,425 | $124K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 4,443 | $117K |
| T1013 | Sign language or oral interpretive services, per 15 minutes | <1% | 6,609 | $117K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,308 | $115K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,600 | $113K |
| 76830 | Ultrasound, transvaginal | <1% | 1,848 | $113K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 1,066 | $106K |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 4,130 | $101K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 10,998 | $96K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,698 | $92K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,668 | $88K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,248 | $84K |
| 83655 | <1% | 6,412 | $81K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 541 | $81K |
| 94726 | <1% | 1,207 | $78K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 4,375 | $78K |
| 90686 | <1% | 11,997 | $76K | |
| 87536 | <1% | 860 | $75K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,996 | $74K |
| 86850 | <1% | 3,328 | $73K | |
| 71045 | Radiologic examination, chest; single view | <1% | 7,423 | $72K |
| 88142 | <1% | 3,150 | $69K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,573 | $66K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 718 | $64K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 573 | $64K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 3,923 | $63K |
| 93971 | <1% | 691 | $62K | |
| 84439 | <1% | 7,372 | $62K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 12,610 | $61K |
| 87088 | <1% | 10,557 | $60K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 570 | $60K |
| 86003 | <1% | 680 | $59K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 6,011 | $58K |
| 82607 | <1% | 4,489 | $55K | |
| 94729 | <1% | 1,192 | $53K | |
| 82728 | <1% | 3,868 | $51K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 38 | $51K |
| 86480 | <1% | 1,004 | $51K | |
| 12001 | <1% | 136 | $49K | |
| 87631 | <1% | 750 | $48K | |
| 99442 | <1% | 1,546 | $48K | |
| 86901 | <1% | 3,410 | $48K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,027 | $48K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 2,125 | $47K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,608 | $46K |
| 87660 | <1% | 3,431 | $46K | |
| 81513 | <1% | 487 | $44K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 321 | $43K |
| 84702 | <1% | 5,779 | $41K | |
| 85027 | <1% | 11,118 | $40K | |
| 76770 | <1% | 328 | $40K | |
| 70491 | <1% | 180 | $39K | |
| 86803 | <1% | 3,983 | $39K | |
| 87510 | <1% | 2,887 | $38K | |
| 87480 | <1% | 2,907 | $38K | |
| 86360 | <1% | 777 | $38K | |
| 70486 | <1% | 305 | $37K | |
| 86900 | <1% | 3,407 | $37K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,947 | $35K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 999 | $35K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 523 | $34K |
| 0223U | <1% | 169 | $32K | |
| 76536 | <1% | 706 | $31K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 26 | $31K |
| 86618 | <1% | 1,044 | $28K | |
| 98968 | <1% | 329 | $28K | |
| 90715 | <1% | 1,327 | $27K | |
| 82746 | <1% | 2,111 | $25K | |
| 71250 | <1% | 155 | $25K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 288 | $25K |
| 86617 | <1% | 818 | $25K | |
| 88304 | <1% | 602 | $24K | |
| 86762 | <1% | 1,653 | $24K | |
| 81001 | <1% | 10,747 | $23K | |
| 83540 | <1% | 4,489 | $23K | |
| 83735 | <1% | 9,718 | $23K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,713 | $23K |
| 84484 | <1% | 8,736 | $23K | |
| 99441 | <1% | 1,145 | $22K | |
| 87340 | <1% | 2,185 | $22K | |
| 84403 | <1% | 867 | $22K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 349 | $22K |
| 83021 | <1% | 1,160 | $21K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 15 | $21K |
| 85610 | <1% | 7,091 | $21K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 607 | $21K |
| 83550 | <1% | 3,609 | $20K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 188 | $20K |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 1,739 | $20K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 354 | $19K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 252 | $19K |
| 82043 | <1% | 3,928 | $19K | |
| 86359 | <1% | 771 | $19K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 491 | $18K |
| 82570 | <1% | 3,806 | $18K | |
| 87186 | <1% | 3,460 | $17K | |
| 85730 | <1% | 3,614 | $16K | |
| 92552 | <1% | 864 | $16K | |
| C1769 | Guide wire | <1% | 675 | $16K |
| 86140 | <1% | 4,985 | $16K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,611 | $16K |
| 87522 | Neg quan hep c or qual rna | <1% | 346 | $16K |
| 73030 | <1% | 876 | $16K | |
| 12002 | <1% | 41 | $15K | |
| 83020 | <1% | 1,144 | $15K | |
| 83001 | <1% | 814 | $15K | |
| 84146 | <1% | 757 | $15K | |
| 73564 | <1% | 793 | $14K | |
| 93970 | <1% | 49 | $14K | |
| 87471 | <1% | 354 | $14K | |
| 81003 | <1% | 9,730 | $13K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 135 | $13K |
| 87077 | <1% | 2,187 | $12K | |
| 83690 | <1% | 7,408 | $12K | |
| 99223 | Prolong inpt eval add15 m | <1% | 77 | $12K |
| 73130 | <1% | 827 | $12K | |
| 86592 | <1% | 3,496 | $12K | |
| 84402 | <1% | 485 | $12K | |
| 99221 | <1% | 178 | $12K | |
| 96376 | <1% | 1,092 | $12K | |
| 73610 | <1% | 736 | $11K | |
| 73630 | <1% | 647 | $11K | |
| 84481 | <1% | 1,170 | $11K | |
| 86787 | <1% | 1,297 | $11K | |
| 87070 | <1% | 1,960 | $11K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 152 | $11K |
| 84480 | <1% | 1,392 | $10K | |
| 83002 | <1% | 577 | $10K | |
| 92551 | <1% | 1,596 | $10K | |
| 86769 | <1% | 202 | $10K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,924 | $10K |
| 86038 | <1% | 1,450 | $9K | |
| 74018 | <1% | 614 | $9K | |
| 86765 | <1% | 664 | $9K | |
| 84703 | <1% | 5,248 | $8K | |
| 83605 | <1% | 2,872 | $8K | |
| 87481 | <1% | 266 | $8K | |
| 90474 | <1% | 1,445 | $8K | |
| 80076 | <1% | 1,032 | $8K | |
| 82784 | <1% | 736 | $8K | |
| 98967 | <1% | 109 | $8K | |
| 76801 | <1% | 111 | $7K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 1,132 | $7K |
| 87653 | <1% | 309 | $7K | |
| 85652 | <1% | 3,743 | $7K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 165 | $7K |
| 86706 | <1% | 710 | $7K | |
| 72100 | <1% | 343 | $7K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 61 | $7K |
| 84550 | <1% | 1,532 | $6K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 19 | $6K |
| 81511 | <1% | 137 | $6K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 115 | $6K |
| 97602 | <1% | 20 | $6K | |
| 99443 | <1% | 72 | $5K | |
| 83970 | <1% | 141 | $5K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 311 | $5K |
| 82248 | <1% | 1,045 | $5K | |
| 82670 | <1% | 188 | $5K | |
| 87040 | <1% | 2,075 | $5K | |
| 86735 | <1% | 524 | $4K | |
| 12011 | <1% | 12 | $4K | |
| 82950 | <1% | 863 | $4K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 30 | $4K |
| 85379 | <1% | 1,438 | $4K | |
| 87205 | <1% | 1,649 | $4K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 41 | $4K |
| 86430 | <1% | 744 | $4K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 309 | $4K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 56 | $3K |
| 86376 | <1% | 250 | $3K | |
| 73110 | <1% | 221 | $3K | |
| 82962 | <1% | 3,181 | $3K | |
| 93925 | <1% | 46 | $3K | |
| 86704 | <1% | 331 | $3K | |
| 82077 | <1% | 1,077 | $3K | |
| 0071A | <1% | 74 | $3K | |
| 72131 | <1% | 13 | $3K | |
| 84153 | <1% | 166 | $3K | |
| 76120 | <1% | 132 | $3K | |
| 84100 | <1% | 646 | $3K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 63 | $3K |
| 0003A | <1% | 67 | $3K | |
| 82105 | <1% | 320 | $2K | |
| 0072A | <1% | 62 | $2K | |
| 0099U | <1% | 40 | $2K | |
| 73502 | <1% | 113 | $2K | |
| 99173 | <1% | 7,295 | $2K | |
| 90734 | <1% | 579 | $2K | |
| 95811 | <1% | 14 | $2K | |
| 11719 | <1% | 279 | $2K | |
| 82150 | <1% | 351 | $2K | |
| 0002A | <1% | 43 | $2K | |
| 0001A | <1% | 42 | $2K | |
| 97162 | <1% | 27 | $2K | |
| 70480 | <1% | 12 | $2K | |
| 72110 | <1% | 45 | $1K | |
| 84436 | <1% | 259 | $1K | |
| 76870 | <1% | 26 | $1K | |
| 87338 | <1% | 174 | $1K | |
| 82550 | <1% | 485 | $1K | |
| 94760 | <1% | 1,052 | $1K | |
| 87899 | <1% | 167 | $1K | |
| 83615 | <1% | 276 | $1K | |
| 99152 | <1% | 66 | $1K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 35 | $1K |
| 86308 | <1% | 391 | $1K | |
| 97166 | <1% | 24 | $1K | |
| 90651 | <1% | 562 | $1K | |
| 82140 | <1% | 95 | $1K | |
| 11056 | <1% | 22 | $1K | |
| 86703 | <1% | 54 | $1K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 43 | $1K |
| 86665 | <1% | 26 | $930.96 | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,126 | $902.95 |
| 90619 | <1% | 284 | $819.97 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,060 | $805.86 |
| 96367 | <1% | 12 | $792.66 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,578 | $791.01 |
| 95806 | <1% | 17 | $731.77 | |
| 86696 | <1% | 52 | $728.72 | |
| 81596 | <1% | 14 | $720.98 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,664 | $689.14 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,597 | $614.99 |
| 85060 | <1% | 37 | $574.24 | |
| 80047 | <1% | 40 | $554.35 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 427 | $552.70 |
| 88311 | <1% | 28 | $520.19 | |
| 99201 | <1% | 12 | $514.08 | |
| 90673 | <1% | 12 | $507.79 | |
| 90670 | <1% | 2,987 | $506.59 | |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | <1% | 141 | $490.37 |
| 82247 | <1% | 105 | $488.76 | |
| 81025 | <1% | 158 | $484.43 | |
| 83525 | <1% | 40 | $460.24 | |
| 86364 | <1% | 56 | $459.72 | |
| 99381 | <1% | 28 | $442.07 | |
| 80074 | <1% | 13 | $440.24 | |
| 82803 | <1% | 97 | $430.51 | |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | <1% | 13 | $419.98 |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 729 | $396.05 |
| 86664 | <1% | 26 | $392.33 | |
| 82040 | <1% | 88 | $381.38 | |
| 80164 | <1% | 55 | $381.19 | |
| A4649 | Surgical supply; miscellaneous | <1% | 14 | $345.83 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,483 | $328.18 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 525 | $324.66 |
| 0011A | <1% | 13 | $319.38 | |
| 84156 | <1% | 88 | $317.46 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 865 | $308.01 |
| 87102 | <1% | 30 | $307.74 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 401 | $307.69 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,758 | $291.21 |
| 86708 | <1% | 27 | $264.72 | |
| 74220 | <1% | 14 | $256.24 | |
| 90662 | <1% | 52 | $255.79 | |
| 83921 | <1% | 12 | $249.06 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 100 | $214.87 |
| 82977 | <1% | 41 | $201.66 | |
| 0124A | <1% | 15 | $200.00 | |
| 87045 | <1% | 25 | $197.95 | |
| 81015 | <1% | 86 | $194.54 | |
| 72040 | <1% | 13 | $184.42 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 489 | $180.41 |
| 82747 | <1% | 13 | $172.76 | |
| 82565 | <1% | 38 | $171.01 | |
| 82945 | <1% | 14 | $164.01 | |
| 83721 | <1% | 26 | $159.84 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 87 | $153.60 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,828 | $151.44 |
| 80320 | <1% | 44 | $142.43 | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 20 | $137.12 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,027 | $126.62 |
| 86141 | <1% | 12 | $113.42 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 237 | $112.65 |
| 73090 | <1% | 26 | $96.26 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 877 | $90.32 |
| G0008 | Administration of influenza virus vaccine | <1% | 67 | $80.50 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 579 | $79.79 |
| 84145 | <1% | 26 | $77.26 | |
| 85018 | <1% | 90 | $74.03 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 213 | $72.60 |
| 90473 | <1% | 12 | $60.00 | |
| 90707 | <1% | 16 | $53.55 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 470 | $44.81 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 52 | $38.44 |
| 73560 | <1% | 12 | $36.00 | |
| 90633 | <1% | 1,001 | $35.70 | |
| 90744 | <1% | 284 | $17.85 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 45 | $17.70 |
| 90785 | <1% | 49 | $11.04 | |
| 82009 | <1% | 19 | $10.45 | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 24 | $10.25 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 15 | $6.72 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 74 | $6.04 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 29 | $3.49 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 13 | $3.27 |
| J1815 | Injection, insulin, per 5 units | <1% | 52 | $3.19 |
| 90697 | <1% | 182 | $0.07 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 856 | $0.06 |
| 90680 | 0% | 1,029 | $0.00 | |
| 90696 | 0% | 37 | $0.00 | |
| 90723 | 0% | 137 | $0.00 | |
| 90698 | 0% | 667 | $0.00 | |
| 90648 | 0% | 612 | $0.00 | |
| 90710 | 0% | 311 | $0.00 | |
| 90685 | 0% | 269 | $0.00 | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 0% | 26 | $0.00 |
| 90700 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGROSSI, BELINDA (PROVIDER CREDENTIALING MANAGER)